Humacyte (NASDAQ:HUMA) Given Overweight Rating at Cantor Fitzgerald

Cantor Fitzgerald restated their overweight rating on shares of Humacyte (NASDAQ:HUMA) in a research note released on Friday, Benzinga reports. They currently have a $13.00 price target on the stock.

Other equities analysts have also issued reports about the company. Benchmark restated a buy rating and set a $15.00 target price on shares of Humacyte in a research report on Thursday, September 5th. BTIG Research upped their target price on shares of Humacyte from $8.00 to $11.00 and gave the company a buy rating in a research note on Monday, July 15th. Finally, EF Hutton Acquisition Co. I upgraded shares of Humacyte to a strong-buy rating in a report on Monday, September 9th. One research analyst has rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of Buy and a consensus target price of $9.80.

Humacyte Trading Up 0.6 %

Shares of NASDAQ HUMA opened at $5.23 on Friday. Humacyte has a fifty-two week low of $1.96 and a fifty-two week high of $9.97. The firm has a market capitalization of $622.81 million, a P/E ratio of -5.23 and a beta of 1.47. The company has a debt-to-equity ratio of 0.61, a current ratio of 5.41 and a quick ratio of 5.41. The company’s 50 day simple moving average is $6.79 and its 200 day simple moving average is $5.63.

Humacyte (NASDAQ:HUMA) last posted its quarterly earnings results on Tuesday, August 13th. The company reported ($0.27) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.04). On average, analysts predict that Humacyte will post -1.09 EPS for the current year.

Insiders Place Their Bets

In related news, Director Brady W. Dougan sold 252,676 shares of the business’s stock in a transaction on Tuesday, August 27th. The shares were sold at an average price of $6.71, for a total value of $1,695,455.96. Following the sale, the director now directly owns 4,306,464 shares of the company’s stock, valued at approximately $28,896,373.44. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Humacyte news, Director Kathleen Sebelius sold 5,182 shares of the company’s stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $5.40, for a total transaction of $27,982.80. Following the completion of the transaction, the director now owns 40,276 shares of the company’s stock, valued at approximately $217,490.40. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Brady W. Dougan sold 252,676 shares of the firm’s stock in a transaction that occurred on Tuesday, August 27th. The stock was sold at an average price of $6.71, for a total transaction of $1,695,455.96. Following the transaction, the director now directly owns 4,306,464 shares of the company’s stock, valued at $28,896,373.44. The disclosure for this sale can be found here. In the last three months, insiders have sold 1,084,153 shares of company stock worth $6,869,996. Company insiders own 23.10% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in HUMA. Endowment Wealth Management Inc. increased its stake in Humacyte by 3.1% in the 2nd quarter. Endowment Wealth Management Inc. now owns 100,518 shares of the company’s stock valued at $482,000 after buying an additional 3,000 shares during the last quarter. nVerses Capital LLC acquired a new stake in shares of Humacyte in the second quarter valued at about $28,000. China Universal Asset Management Co. Ltd. raised its holdings in Humacyte by 65.9% during the first quarter. China Universal Asset Management Co. Ltd. now owns 19,883 shares of the company’s stock worth $62,000 after acquiring an additional 7,897 shares in the last quarter. The Manufacturers Life Insurance Company boosted its position in Humacyte by 32.5% during the second quarter. The Manufacturers Life Insurance Company now owns 34,919 shares of the company’s stock valued at $168,000 after purchasing an additional 8,557 shares during the last quarter. Finally, Victory Capital Management Inc. bought a new position in Humacyte in the fourth quarter valued at approximately $29,000. Institutional investors and hedge funds own 44.71% of the company’s stock.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.